Impaired Verbal Memory Recall in Patients With Axonal Degeneration and Serum Glycine-Receptor Autoantibodies-Case Series.

cognitive impairment glycine receptor antibody memory recall neurodegeneration tau protein

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2021
Historique:
received: 17 09 2021
accepted: 21 12 2021
entrez: 14 2 2022
pubmed: 15 2 2022
medline: 15 2 2022
Statut: epublish

Résumé

Glycine receptor antibody-associated neuropsychiatric disease is currently known to be dominated by the phenotypes stiff-person syndrome and progressive encephalomyelitis entailing rigidity and myoclonus. In our case series we aim to depict the less-often reported feature of cognitive impairment associated with glycine receptor antibodies. We investigated five patients with cognitive impairment varying from mild cognitive impairment to dementia associated with serum glycine receptor antibodies. Mild and major neurocognitive disorders were diagnosed according to the DSM-5 (fifth edition of the Diagnostic and Statistical Manual of Mental Disorders). Neuropsychology via Consortium to Establish a Registry for Alzheimer's Disease (CERAD) testing results, psychopathology data via the Manual for the Assessment and Documentation of Psychopathology in Psychiatry (AMDP), cerebrospinal fluid analysis and magnetic resonance imaging data were retrospectively analyzed from patient files. We identified five patients with cognitive impairment as the main neuropsychiatric feature associated with serum glycine receptor antibodies. One patient also presented akinetic rigidity syndrome. The psychopathology comprised disorders of attention and memory, orientation, formal thought, and affect. In addition to suffering deficits in verbal memory function, figural recall, phonematic fluency, and globally deteriorated cognitive function, these patients presented seriously impaired memory recall in particular. Tau protein and phosphorylated tau protein 181 were elevated in 75% of patients. Our results suggest that axonal neurodegeneration and especially impaired verbal memory recall in addition to deficits in verbal and figural memory characterize patients with progressive cognitive impairment associated with glycine receptor antibodies. This unresolved issue should be clarified by researchers to discover whether axonal degeneration is merely an age-related phenomenon or one related to glycine-receptor autoantibodies in old age. Cognitive impairment as a neuropsychiatric syndrome of glycine-receptor antibody disease is a potential, conceivable, but so far unproven additional feature requiring deeper large-scale investigations and consideration during differential diagnosis in memory clinics.

Sections du résumé

BACKGROUND BACKGROUND
Glycine receptor antibody-associated neuropsychiatric disease is currently known to be dominated by the phenotypes stiff-person syndrome and progressive encephalomyelitis entailing rigidity and myoclonus. In our case series we aim to depict the less-often reported feature of cognitive impairment associated with glycine receptor antibodies.
METHODS METHODS
We investigated five patients with cognitive impairment varying from mild cognitive impairment to dementia associated with serum glycine receptor antibodies. Mild and major neurocognitive disorders were diagnosed according to the DSM-5 (fifth edition of the Diagnostic and Statistical Manual of Mental Disorders). Neuropsychology via Consortium to Establish a Registry for Alzheimer's Disease (CERAD) testing results, psychopathology data via the Manual for the Assessment and Documentation of Psychopathology in Psychiatry (AMDP), cerebrospinal fluid analysis and magnetic resonance imaging data were retrospectively analyzed from patient files.
RESULTS RESULTS
We identified five patients with cognitive impairment as the main neuropsychiatric feature associated with serum glycine receptor antibodies. One patient also presented akinetic rigidity syndrome. The psychopathology comprised disorders of attention and memory, orientation, formal thought, and affect. In addition to suffering deficits in verbal memory function, figural recall, phonematic fluency, and globally deteriorated cognitive function, these patients presented seriously impaired memory recall in particular. Tau protein and phosphorylated tau protein 181 were elevated in 75% of patients.
CONCLUSIONS CONCLUSIONS
Our results suggest that axonal neurodegeneration and especially impaired verbal memory recall in addition to deficits in verbal and figural memory characterize patients with progressive cognitive impairment associated with glycine receptor antibodies. This unresolved issue should be clarified by researchers to discover whether axonal degeneration is merely an age-related phenomenon or one related to glycine-receptor autoantibodies in old age. Cognitive impairment as a neuropsychiatric syndrome of glycine-receptor antibody disease is a potential, conceivable, but so far unproven additional feature requiring deeper large-scale investigations and consideration during differential diagnosis in memory clinics.

Identifiants

pubmed: 35153852
doi: 10.3389/fpsyt.2021.778684
pmc: PMC8831910
doi:

Types de publication

Journal Article

Langues

eng

Pagination

778684

Informations de copyright

Copyright © 2022 Hansen, Bartels, Stöcker, Wiltfang and Fitzner.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Elife. 2020 Jun 24;9:
pubmed: 32579109
Ann Neurol. 2020 Sep;88(3):544-561
pubmed: 32588476
Clin Neurol Neurosurg. 2021 Sep;208:106807
pubmed: 34325335
JAMA Neurol. 2016 Jun 1;73(6):714-20
pubmed: 27065452
J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):462-5
pubmed: 12640064
Eur J Neurol. 2018 Oct;25(10):1290-1298
pubmed: 29904974
Neurol Neuroimmunol Neuroinflamm. 2018 Jan 23;5(2):e438
pubmed: 29464188
Neuropathol Appl Neurobiol. 2021 Feb;47(2):316-327
pubmed: 32910464
Prog Neurobiol. 2010 Aug;91(4):349-61
pubmed: 20438799
Neurol Neuroimmunol Neuroinflamm. 2019 Jul 01;6(5):e592
pubmed: 31355325
Dev Neurobiol. 2017 Dec;77(12):1430-1441
pubmed: 29057625
Brain Sci. 2020 Jun 23;10(6):
pubmed: 32585946
Brain. 2014 Aug;137(Pt 8):2178-92
pubmed: 24951641
Brain Behav Immun Health. 2020 Oct 01;9:100154
pubmed: 34589896
Proc Natl Acad Sci U S A. 2021 Jul 6;118(27):
pubmed: 34187890
Front Aging Neurosci. 2021 Jul 28;13:711195
pubmed: 34393763
Brain. 2019 Nov 1;142(11):3398-3410
pubmed: 31591639
J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1399-401
pubmed: 21148607
Brain Res. 1992 Jan 31;571(1):1-18
pubmed: 1611482
JAMA Neurol. 2013 Jan;70(1):44-50
pubmed: 23090334

Auteurs

Niels Hansen (N)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.

Claudia Bartels (C)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.

Winfried Stöcker (W)

Euroimmun Reference Laboratory, Lübeck, Germany.

Jens Wiltfang (J)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
Neurosciences and Signaling Group, Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal.

Dirk Fitzner (D)

Department of Neurology, University Medical Center of Göttingen, Göttingen, Germany.

Classifications MeSH